Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 8/20 | 0.57 |
| ▸ | CBLB | Q13191 | 9/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | MYLK | Q15746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL944056 | 0.90 | MAP3K5 (0.60) | MAP3K5CBLBLMNAGAACLK1 | |
| SCHEMBL947306 | 0.89 | MAP3K5 (0.58) | MAP3K5CBLBLMNAGAACLK1 | |
| SCHEMBL945555 | 0.88 | MAP3K5 (0.59) | MAP3K5CBLBLMNAGAACLK1 | |
| SCHEMBL945190 | 0.87 | MAP3K5 (0.63) | MAP3K5CBLBLMNAGAACLK1 | |
| SCHEMBL945552 | 0.87 | MAP3K5 (0.63) | MAP3K5CBLBLMNAGAACLK1 | |
| SCHEMBL945857 | 0.87 | MAP3K5 (0.58) | MAP3K5CBLBLMNAGAACLK1 | |
| SCHEMBL944241 | 0.86 | MAP3K5 (0.62) | MAP3K5CBLBLMNAGAACLK1 | |
| SCHEMBL943985 | 0.86 | MAP3K5 (0.58) | MAP3K5CBLBLMNAGAACLK1 | |
| SCHEMBL946017 | 0.85 | MAP3K5 (0.62) | MAP3K5CBLBLMNAGAACLK1 | |
| SCHEMBL944192 | 0.85 | MAP3K5 (0.56) | MAP3K5CBLBLMNAGAACLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180311247-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | GILEAD SCIENCES, INC. | 2018-11-01 | — | — | US | disclosed |
| US-8552196-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8378108-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20130035339-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC (US) | 2013-02-07 | — | — | US | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, AIFM1 | MAP3K5 16/4885CBLB 3791/4885LMNA 1002/4885 |
| US-20180311247-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | BRD4, JAK2, JAK1 | MAP3K5 105/4885CBLB 1011/4885LMNA 4226/4885 |
| US-20130035339-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, MAP3K6 | MAP3K5 13/4885CBLB 3694/4885LMNA 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.